Skip to main content

Table 3 Distribution of outcomes after discontinuation of lamivudine, adefovir, entecavir, and telbivudine

From: Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative

NUCs

Sustained response - no. (%)

Relapse - no. (%)

LAM

11 (24.4)

2 (10.5)

ADV

27 (60.0)

15 (78.9)

ETV

5 (11.1)

2 (10.5)

LDT

2 (4.4)

0

  1. LAM, lamivudine; ADV, adefovir; ETV, entecavir; LDT, telbivudine.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us